Product Dossier
OVIDREL
Product Dossier for OVIDREL (Choriogonadotropin alfa, Merck Healthcare). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Merck Healthcare
- Active ingredient: Choriogonadotropin alfa
- Therapeutic area: Reproductive Health
- Same area: ESTRADOT
- Same area: PROVERA
What it is
OVIDREL is choriogonadotropin alfa (recombinant human chorionic gonadotropin) supplied as a solution for injection in pre-filled syringes and pre-filled pens, each containing 250 micrograms in 0.5 mL.
Approved indications
— Treatment of infertility not associated with assisted reproductive technology.
PBS listing
OVIDREL 250 micrograms in 0.5 mL solution for injection is available on the PBS in two formulations: pre-filled syringes and pre-filled pens. The pre-filled syringe has an ex-manufacturer price of A$112.80, while the pre-filled pen has an ex-manufacturer price of A$65.59. Both formulations are listed with streamlined, restricted access.
Regulatory history
OVIDREL was first registered on the ARTG in September 2003 as a pre-filled syringe formulation. A pre-filled pen formulation was registered in July 2010. In September 2021, the PBAC recommended OVIDREL for the treatment of infertility not associated with assisted reproductive technology. The PBAC again recommended the medicine in September 2023 for infertility indications other than assisted reproductive technology.